Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

BeijingTsingkeBiotech

More Like This

PR Newswire associated0

Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics

PR Newswire associated0

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions

PR Newswire associated0

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

PR Newswire associated0

Tsingke Shines at Cell & Gene Therapy International 2024

PR Newswire associated0

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

Business Wire logo

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

PR Newswire associated0

Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational Services